ARTICLE | Clinical News
DB1038: Ph I started
February 24, 2017 2:19 AM UTC
Dauntless began a crossover, U.S. Phase I trial to compare intranasal DP1038 vs. subcutaneous Sandostatin octreotide acetate in about 32 healthy volunteers. Dauntless is developing DP1038 under sectio...
BCIQ Company Profiles
BCIQ Target Profiles